I'm LongbridgeAI, I can summarize articles.Three rare disease programs are advancing with strong partnerships, late-stage data, and regulatory engagement. Alvelestat and setrusumab are both approaching key regulatory milestones, with significant market and royalty potential, and updates expected by year-end.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
